75.988 Medicare and ‘Off Label’ Uses of Drugs: MSSNY confirms its strong support for the autonomous clinical decision-making authority of physicians to prescribe medications for ‘off-label” use. (HOD 2004-67; Modified and reaffirmed HOD 2014; Reaffirmed HOD 2015-53; Reaffirmed HOD in lieu of 2022-55)
75.987 Medical Marijuana: SUNSET HOD 2020
75.986 Herbal Supplements: (1) MSSNY will work with the American Medical Association to educate physicians and the public to report potential adverse events associated with dietary supplements and herbal remedies to help support FDA’s database of adverse event information on these forms of alternative/complementary therapies; (2) MSSNY, in conjunction with the AMA, supports efforts to
75.985 Availability of Nicotine Replacement: MSSNY supports the sale of nicotine replacement products in settings where cigarettes are sold and will work with the NYS Department of Health to make free nicotine replacement products available in physicians’ offices. (HOD 2006-161; Amended HOD 2016; Reaffirmed HOD 2019 in lieu of res 250)
75.984 Medical Use of Marijuana/Synthetic Cannabinoids: MSSNY encourages additional research on the use of cannabinoid products in the treatment of illness and the relief of human suffering without penalty. (HOD 2007-151; Modified and Reaffirmed HOD 2017; Reaffirmed HOD 2018 in lieu of res 166; Reaffirmed HOD 2019 in lieu of res 172)
75.983 Limiting Coverage for Psychiatric Drugs: MSSNY will urge the appropriate state agency and/or State Legislature to prohibit the practice of health insurance companies restricting access to psychiatric drugs by (1) requiring failure of a generic drug prior to permitting coverage for a non-generic drug; (2) limiting doses by number of pills per day; or (3)
75.982 Extend Phase-out Period for Proven CFC Inhalers: (HOD 2008-170; SUNSET HOD 2018)
75.981 “Pay for Delay” Arrangements by Pharmaceutical Companies: MSSNY will forward a resolution to the American Medical Association exhorting that organization to support the Federal Trade Commission in its efforts to stop these “pay for delay” arrangements. (HOD 2008-207; Reaffirmed HOD 2018)
75.980 Inappropriate Incentives for Recommending Generic Drugs over Brand Name Drugs: MSSNY will introduce a resolution at the June 2009 Annual Meeting of the American Medical Association (AMA) calling upon the Centers for Medicare & Medicaid Services to abolish the provision of providing incentives for pharmacists to “push” generic drugs over brand name drugs; and, through
75.979 Medical Marijuana: MSSNY will take a leadership role in the development of any regulations resulting from the passage of state legislation pertaining to medical marijuana and also request the American Medical Association’s assistance in seeking a reversal of the Executive Order pertaining to the prosecution of physicians who prescribe or advise medical marijuana, legally under
